CSL Ltd. — Investor Presentation 2024

Apr 22, 2024

For immediate release

23 April 2024

==> picture [596 x 198] intentionally omitted <==

Shareholder Information Meetings

Please find attached CSL Limited’s presentation given at the Shareholder Information Meetings in Perth and Adealaide on 23 and 24 April 2024.

A recording of the presentation will be avaialble in the ‘Investors’ section of the Company website at www.csl.com under Presentations.

Authorised by:

Fiona Mead

Company Secretary

For further information, please contact:

Investors: Bernard Ronchi Director, Investor Relations CSL Limited P: +61 3 9389 3470

• E: bernard.ronchi@csl.com.au

==> picture [134 x 98] intentionally omitted <==

CSL Limited Shareholder Briefing April 2024

Joy Linton CFO

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL ) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange ( ASX ), available at www.asx.com.au This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

Legal Notice

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", “project,” "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements . Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, advances in environmental protection processes, uncertainty and disruption caused by the COVID-19 pandemic and CSL’s ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

2

Joy Linton CFO

==> picture [109 x 10] intentionally omitted <==

==> picture [34 x 19] intentionally omitted <==

3

Leading Positions in Large, Growing Markets Global #1

in plasma protein therapies ~$38 billion industry Global #2

in influenza vaccines ~$7 billion industry

Global #1

in iron ~$5 billion industry

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

4

Our Businesses

==> picture [119 x 61] intentionally omitted <==

==> picture [224 x 47] intentionally omitted <==

==> picture [227 x 49] intentionally omitted <==

==> picture [181 x 41] intentionally omitted <==

Biotherapies & Rare Disease

Vaccines

Iron Deficiency & Nephrology

Driven by Our Promise

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

5

Global Manufacturing Presence

==> picture [161 x 35] intentionally omitted <==

==> picture [252 x 124] intentionally omitted <==

Bern, Switzerland

==> picture [252 x 124] intentionally omitted <==

Broadmeadows, Australia

==> picture [252 x 124] intentionally omitted <==

Marburg, Germany

==> picture [104 x 10] intentionally omitted <==

==> picture [252 x 124] intentionally omitted <==

Kankakee, United States

==> picture [252 x 124] intentionally omitted <==

Wuhan, China

==> picture [67 x 50] intentionally omitted <==

6

Global Manufacturing Presence

==> picture [158 x 34] intentionally omitted <==

==> picture [233 x 124] intentionally omitted <==

Parkville, Australia

==> picture [233 x 124] intentionally omitted <==

Holly Springs, United States

==> picture [118 x 27] intentionally omitted <==

==> picture [230 x 124] intentionally omitted <==

St Gallen, Switzerland

==> picture [233 x 124] intentionally omitted <==

Liverpool, United Kingdom

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

7

Strong and Consistent Growth

==> picture [846 x 350] intentionally omitted <==

----- Start of picture text -----

Revenue Net Profit Dividends
US$
$2.36
$2.6b NPATA
$13.3b
10% 8% 9%
CAGR CAGR CAGR
$1.2b
$1.02
$5.1b
2013 2023 2013 2023 2013 2023
----- End of picture text -----

==> picture [104 x 10] intentionally omitted <==

CAGR – Compound average growth rate

==> picture [67 x 50] intentionally omitted <==

8

1H24 Strong performance[1] Revenue +11%, NPATA[2,3] +13%, NPAT +20%

Revenue by Segment

CSL Behring

CSL Seqirus

==> picture [593 x 288] intentionally omitted <==

----- Start of picture text -----

by Segment
Solid performance
in a challenging season
•
FLUAD [®] +14%
•
Approval for world first sa-mRNA
Seqirus
COVID vaccine
+2%
•
aQIVc phase 3 - last patient enrolled
Behring $8,053m
+14%
CSL Vifor Vifor
nc [4]
Well prepared for
transitioning Iron market
•
Successful TAVNEOS [®] EU launch
•
Strong conversion to MIRCERA [®]
----- End of picture text -----

• Strong growth across the portfolio especially Ig

• • Ig +23%, KCENTRA[®] +12%, HAEGARDA[®] +9%

• • Gross margin recovery underway

• Good progress with plasma initiatives

• Garadacimab filed

==> picture [67 x 50] intentionally omitted <==

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail..

2. NPATA is defined as the statutory net profit after tax before impairment and amortisation of acquired intellectual property, business acquisition and integration costs and unwind of the inventory fair value uplift

==> picture [104 x 10] intentionally omitted <==

3. Attributable to the shareholders of CSL Limited

4.Not comparable

9

CSL Share Price v 10 Year US Govt Bond Rate

==> picture [871 x 432] intentionally omitted <==

----- Start of picture text -----

$ 320 5.1 %
4.9
300
FY23 4.7
280 Result
CSL 112
s 4.5
& 1H24
Results
CSL 260 4.3
Bond
Share
Rate
Price 4.1
240
GLP-1 3.9
220 Findings
Capital 3.7
Markets
Day
200 3.5
Jul-23 Aug-23 Aug-23 Sep-23 Oct-23 Nov-23 Dec-23 Jan-24 Feb-24 Mar-24
----- End of picture text -----

10

Long Term, Sustainable Growth

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

1 Consistent strategy & disciplined execution 2 Targeted R&D with continuous innovation 3 Commitment to sustainability

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

11

Long Term, Sustainable Growth

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

1 Consistent strategy & disciplined execution 2 Targeted R&D with continuous innovation 3 Commitment to sustainability

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

12

Our 2030 Strategy

Focusing Innovating Delivering Growing across our in therapeutic reliable supplies of our pipeline with areas where organization our products as sustainable, trusted we excel efficiently as possible R&D platforms

Transforming our digital intellect and technologies

==> picture [104 x 10] intentionally omitted <==

==> picture [569 x 296] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

13

Disciplined Management of Capital

==> picture [70 x 70] intentionally omitted <==

Growing Cash Earnings

Maintain strong balance sheet

Returns to Re-invest in Capital shareholders the Business structure

Partnering approach

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

14

Long Term, Sustainable Growth

==> picture [72 x 72] intentionally omitted <==

1 Consistent strategy & disciplined execution 2 Targeted R&D with continuous innovation 3 Commitment to sustainability

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

15

Our Therapeutic Areas and Platforms

==> picture [852 x 170] intentionally omitted <==

==> picture [192 x 192] intentionally omitted <==

New: Nephrology

==> picture [67 x 50] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

16

CSL R&D Portfolio – FY24

As at Capital Markets Day 16 Oct 2023

Phase I

Phase II

Phase III

Registration/Post-Registration

==> picture [861 x 380] intentionally omitted <==

----- Start of picture text -----

CSL889 Anumigilimab (CSL324) HIZENTRA [®] HAEGARDA [®] FILSPARI  ( Sparsentan) AUDENZ™
Hemopexin (SCD) Anti-G-CSFR mAb (HS) (DM) (HAE) Dual ETA & AT1 antagonist Adjuvanted Cell-based
(IgAN) Monovalent Influenza A
Anumigilimab (CSL324) VAMIFEPORT KCENTRA [®] HIZENTRA [®] (H5N1) Vaccine
Anti-G-CSFR mAb Ferroportininhibitor 4F-PCC (Trauma) (SCIg) 20% Liquid KORSUVA [® ] /KAPRUVIA [®] FOCLIVIA [®] /AFLUNOV [®]
(CAP ARDS) (SCD) KOR. agonist Adjuvanted Egg-based
CSL1 1 2 PRIVIGEN [®] (CKD-aP) Influenza A (H5N1) Vaccine
Trabikibart (CSL311) CSL301 apoA-I (AMI) (IVIg) 10% Liquid
Anti-Beta Common mAb α2AP mAb (PE) RAYALDEE [®] FLUAD [® ] Trivalent
SNF472 Garadacimab Oral ext. release calcifediol Adjuvanted Egg-based
CSL787 Garadacimab Calcification inhibitor Anti-FXIIa mAb (HAE) (SHPT) Influenza Vaccine
Nebulised Ig Anti-FXIIa mAb (ILD/IPF) (CUA-ESKD) AFSTYLA [®] TAVNEOS [®] FLUAD [® ] Quadrivalent
C1 Inhibitor Clazakizumab FILSPARI  ( Sparsentan) rFVIII (Haem A) Oral C5a receptor inhibitor Adjuvanted Egg-based Influenza Vaccine
(AIS) Dual ETA & AT1 antagonist (AAV)
Anti-IL-6 mAb (ESKD) (FSGS) IDELVION [®]
FLUCELVAX [® ]
CSL040 Mavrilimumab rFIX-FP (Haem B) VELPHORO [®] Quadrivalent
Complement R1 Inhibitor Clazakizumab Sucroferric oxyhydroxide Cell-based Influenza Vaccine
Anti-GM-CSFR mAb Anti-IL-6 mAb (ca-AbMR) HEMGENIX [ ®] (Serum P control in CKD)
SQ009 (GCA, COVID) (Haem B)
ARCT154
Cell-based Influenza CSL964 VELTASSA [®] sa-mRNA Vaccine
(H2N3) Vaccine Eblasakimab (CSL334) Alpha 1 Antitrypsin ZEMAIRA [®] /RESPREEZA [®] Oral potassium binder (COVID)
Anti-IL-13R mAb (AD) (Treatment of aGvHD) Alpha 1 Antitrypsin (HK)
SQ012
sa-mRNA Influenza INJECTAFER [®]
(H5N1) Vaccine CSL964 (Ferric carboxymaltose)
Alpha 1 Antitrypsin
(HF-ID)
(Prevention of aGvHD)
ARCT2138
sa-mRNA Quadrivalent
Influenza Vaccine SQ036 (aQIVc)
Adjuvanted Cell-based
Quadrivalent Influenza
LASN01 Vaccine
Anti-IL-11R mAb
(IPF,TED)
Immunology Haematology Respiratory Cardiovascular & Nephrology &
Metabolic Transplant
17 Vaccines CSL Vifor Outlicensed
Partnered Projects
Programs
----- End of picture text -----

17

R&D Focus

Investments Coming to Fruition

==> picture [69 x 70] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Deliver a Promising Portfolio

Strengthen our Core Platforms

• Flu Cell Culture yield

• CSL112

• Garadacimab HAE

• Iron evidence & optimisation

• Clazakizumab ca-AbMR

• Patient Blood Management

• KCENTRA[®] Trauma

• CSL964 aGvHD

• Ig yield

• Sparsentan

• sa-mRNA for COVID (near term) & Influenza (medium term)

• aQIVc

==> picture [104 x 10] intentionally omitted <==

==> picture [291 x 474] intentionally omitted <==

----- Start of picture text -----

As at Capital
Markets Day
16 Oct 2023
----- End of picture text -----

==> picture [67 x 50] intentionally omitted <==

18

Long Term, Sustainable Growth

==> picture [72 x 72] intentionally omitted <==

1 Consistent strategy & disciplined execution 2 Targeted R&D with continuous innovation 3 Commitment to sustainability

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

19

==> picture [266 x 200] intentionally omitted <==

CSL is committed to a healthier world. Our vision is a sustainable future for our employees, communities, patients and donors, inspired by innovative science and a valuesdriven culture

==> picture [104 x 10] intentionally omitted <==

Creating Value

==> picture [56 x 56] intentionally omitted <==

A healthy, more productive society Sustainable financial growth Social and economic opportunity

==> picture [79 x 79] intentionally omitted <==

==> picture [88 x 87] intentionally omitted <==

==> picture [106 x 106] intentionally omitted <==

Our Promise to patients

==> picture [67 x 50] intentionally omitted <==

20

Sustainability Framework

ENVIRONMENTAL

Delivering on our promise to preserve a healthier planet

• Environmental Considerations

• Reduce Carbon Emissions

• Reduce Waste & Emissions in the Supply Chain

==> picture [104 x 10] intentionally omitted <==

SOCIAL

Providing better care for brighter days ahead

• Donor Experience

• Patient & Public Health Leader

• Access to Our Therapies

SUSTAINABLE WORKFORCE

It’s the people behind our promise that makes us different

• Employee rights and DEI

• Talent attraction, development and retention

• Supplier diversity

==> picture [67 x 50] intentionally omitted <==

21

Positioned for Annual Double-Digit Earnings Growth

==> picture [77 x 77] intentionally omitted <==

Leading positions in high growth markets

==> picture [74 x 74] intentionally omitted <==

Robust R&D Portfolio

==> picture [83 x 84] intentionally omitted <==

Yield & capacity expansion

==> picture [78 x 78] intentionally omitted <==

Disciplined capital allocation for growth

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

22

==> picture [122 x 108] intentionally omitted <==

Thank You / Questions

==> picture [104 x 10] intentionally omitted <==

==> picture [67 x 50] intentionally omitted <==

23